The Food and Drug Administration (FDA) and European Medicines Agency approved T-DXd for treating unresectable or metastatic HER2-positive BC who have been pretreated with two or more anti-HER2-based regimens.3 The gene discussed is ERBB2; the disease is breast cancer.